 | |
- close
- close
|
Business Wire
Nov 12
Comment
Adolor Corporation (NasdaqGM:ADLR) today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in
StreetInsider.com
Oct 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Adolor+Corp.+%28ADLR%29+Posts+Q3+Loss+of+%240.24%2C+Misses+Estimates/5054471.html for the full story.
Business Wire
Oct 29
Comment
Adolor Corporation (NasdaqGM:ADLR) today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and
Business Wire
Oct 22
Comment
Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:45 a.m. ET on Thursday, October 29, 2009, to discuss third quarter 2009 financial results. To participate in the audio portion and have the opportunity to
FierceBiotech
Sep 22
Comment
Adolor has plunked down $2 million upfront and committed to pay $70 million more in milestones for Eli Lilly's OpRA III, a clinical stage product being developed for opioid bowel dysfunction. Adolor says it will soon launch a new trial for the...
Business Wire
Sep 21
Comment
Adolor Corporation (NasdaqGM:ADLR) today announced that it has acquired from Eli Lilly and Company (“Lilly”) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate. OpRA III is a potent opioid receptor antagonist, with
Business Wire
Sep 21
Comment
Adolor Corporation (NasdaqGM:ADLR) today announced that management will present at the UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 4:00 P.M. Eastern Time. The conference is being held at the Grand Hyatt, New York, New
Marketwire
Aug 20
Comment
EXTON, PA and PHILADELPHIA, PA -- (Marketwire) -- 08/20/09 -- Adolor Corporation (NASDAQ: ADLR) and GlaxoSmithKline (NYSE: GSK) today announced that an economic analysis of Phase 3 clinical trial data reported that the use of ENTEREG after bowel
StreetInsider.com
Jul 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Adolor+%28ADLR%29+Reports+In-Line+Q2+Loss+of+%240.36/4826491.html for the full story.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
ADLR AT A GLANCE
References
| ||||||
|
|
